Evidence map›Paper›PMID 42215440›Full record

ArticleCell death & disease2026

RACK1 governs a dual metabolic switch in lung adenocarcinoma through c-Src/G6PD and TRIM21/LDHA Axes.

Huimin Wan, Chao Li, Mengqian Xia, Lin Dong, Tingting Lin, Weiwei Guo, Fanglei Jiao, Jingjing Lu, Zhongliang Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huimin Wan *Department of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Chao Li *Department of General Surgery, Zhongshan Hospital, School of Medicine, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-9768-4004
Mengqian Xia *Department of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Lin DongThoracic Surgery Department, East Hospital (South), School of Medicine, Tongji University, Shanghai, China.
Tingting LinDepartment of Respiratory Medicine, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, China.
Weiwei GuoRehabilitation Medicine Center, Shanghai Pudong New District Zhoupu Hospital, Shanghai, China.
Fanglei JiaoThoracic Surgery Department, East Hospital (South), School of Medicine, Tongji University, Shanghai, China.
Jingjing LuDepartment of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. 1600074@tongji.edu.cn.ORCID http://orcid.org/0000-0003-2841-3117
Zhongliang GuoDepartment of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. gzl@tongji.edu.cn.ORCID http://orcid.org/0000-0003-0414-379X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) remains a lethal malignancy plagued by therapy resistance and metabolic adaptability. This study identifies the scaffold protein RACK1 as a central regulator of LUAD pathogenesis and metabolic reprogramming. RACK1 is frequently upregulated in LUAD, where its expression correlates with advanced stage and poor prognosis. Mechanistically, RACK1 co-activates two pivotal metabolic pathways: it stabilizes LDHA by competing with its E3 ligase TRIM21, thereby enhancing glycolysis, and it scaffolds c-Src to phosphorylate and activate G6PD, fueling the pentose phosphate pathway. This dual metabolic switch promotes biomass production, redox balance, and drives aggressive tumor phenotypes. Crucially, combined targeting of RACK1 with c-Src or LDHA inhibition yielded synergistic anti-tumor effects in vivo, significantly surpassing monotherapies. Our findings establish RACK1 as a master metabolic regulator and propose a promising combinatorial therapeutic strategy for LUAD.

Indexed as

Adenocarcinoma of LungGlucosephosphate DehydrogenaseLung NeoplasmsNeoplasm ProteinsReceptors for Activated C KinaseRibonucleoproteinssrc-Family KinasesAnimalsCell Line, TumorGene Expression Regulation, NeoplasticGlycolysisHumansMetabolic ReprogrammingMiceSignal TransductionSS-A AntigenGlucosephosphate DehydrogenaseNeoplasm ProteinsRACK1 protein, humanReceptors for Activated C KinaseRibonucleoproteinssrc-Family KinasesSS-A AntigenTRIM21 Protein

Identifiers

PMID42215440
PMCPMC13424137

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.